SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (2163)3/16/2011 12:46:44 PM
From: tuck  Respond to of 2173
 
Amylin and Takeda have suspended the Symlin/metreleptin obesity study due to an antibody related lab finding from a couple of patients in a previous study.

investors.amylin.com

This may be only a temporary road block -- indeed, the market is treating it as such, since Amylin is up a bit on a bad day for the market -- or it may not.

Cheers, Tuck